Emcure Pharmaceuticals Ltd Capital Reinvestment Ratio
Emcure Pharmaceuticals Ltd capital reinvestment ratio. Emcure Pharmaceuticals Ltd (EMCURE) has a Capital Reinvestment Ratio of 0.50x as of September 2025, meaning it reinvests 1% of its operating cash flow (Rs2.56 Billion) in capital expenditures (Rs1.29 Billion). See EMCURE FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Emcure Pharmaceuticals Ltd (2022–2026)
Capital reinvestment ratio of Emcure Pharmaceuticals Ltd from 2022 to 2026. This chart tracks Emcure Pharmaceuticals Ltd's Capital Reinvestment Ratio across 5 annual periods. See EMCURE free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Emcure Pharmaceuticals Ltd Capital Reinvestment Ratio by Year (2022–2026)
Emcure Pharmaceuticals Ltd capital reinvestment ratio by year from 2022 to 2026. For the full cash flow conversion analysis, see cash efficiency ratio of Emcure Pharmaceuticals Ltd.
| Year | Reinvestment Ratio | Operating CF (INR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2026 | 0.42x | Rs8.51 Billion | Rs3.61 Billion | ▼ -11.3% |
| 2025 | 0.48x | Rs8.52 Billion | Rs4.07 Billion | ▲ +70.7% |
| 2024 | 0.28x | Rs10.97 Billion | Rs3.07 Billion | ▼ -48.2% |
| 2023 | 0.54x | Rs7.47 Billion | Rs4.03 Billion | ▲ +4.5% |
| 2022 | 0.52x | Rs7.68 Billion | Rs3.97 Billion | — |